Abcam plc (ABC) is a leading biotechnology business based in the UK. Abcam is listed on the London Stock Exchange (LSE) and employs 1,492 staff. All prices are listed in pence sterling.
|52-week range||939.9511p - 1735p|
|50-day moving average||1525.1765p|
|200-day moving average||1378.5845p|
|Wall St. target price||1334.5p|
|Dividend yield||0.12p (0.88%)|
|Earnings per share (TTM)||6p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Abcam stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcam's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abcam's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 283x. In other words, Abcam shares trade at around 283x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Abcam's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £60.4 million.
The EBITDA is a measure of a Abcam's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£260 million|
|Operating margin TTM||17.12%|
|Gross profit TTM||£180.2 million|
|Return on assets TTM||4.42%|
|Return on equity TTM||2.82%|
|Market capitalisation||£3.8 billion|
TTM: trailing 12 months
Dividend payout ratio: 202.17% of net profits
Recently Abcam has paid out, on average, around 202.17% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.88% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abcam shareholders could enjoy a 0.88% return on their shares, in the form of dividend payments. In Abcam's case, that would currently equate to about 0.12p per share.
Abcam's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 19 March 2020 (the "ex-dividend date").
Abcam's shares were split on a 5:1 basis on 15 November 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Abcam shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Abcam shares which in turn could have impacted Abcam's share price.
Over the last 12 months, Abcam's shares have ranged in value from as little as 939.9511p up to 1735p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Abcam's is 0.4132. This would suggest that Abcam's shares are less volatile than average (for this exchange).
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.